**Original Research Article**

**Patient characteristics and clinical manifestations of systemic lupus erythematosus and their association with elevated IgG antibody against viral capsid antigen (VCA) of Epstein-Barr virus in Yemen.**

**ABSTRACT**

**Background and aims**: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with multiple organ damage due to the production of auto-antibodies, including auto-antibodies to antigens of brain, renal and vascular tissues, ribosomes, nuclear antigens, and phospholipids. Epstein-Barr virus (EBV) is a gamma-herpes virus that ubiquitously infects the majority of the world’s population. EBV maintains latency in B cells and occasionally reactivates the lytic cycle, EBV infection elicits an IgG response to viral capsid antigen (VCA), followed by an IgG response to early antigen (EA). Several recent studies connected EBV infection with clinical features and happening of SLE; so this study was carried out to determine patient characteristics and clinical manifestations of systemic lupus erythematosus and find out the association of positive IgG with high titer for EBV-VCA with clinical manifestation for SLE patients.

**Materials and Methods:** In this cross-sectional study, 142 patients with SLE diagnosed based on American College of Rheumatology criteria were selected. All were included in the study after obtaining informed consent for participation. Whole blood samples were taken and serum were separated to determine anti-EBV IgG antibodies using the ELISA method and assessment with the SLE. Data from patients were collected from all patients using predesigned questionnaire include demographic data, clinical data, and laboratory results. Data were analyzed using Epi Info 7.2. Express the quantitative data as mean values, standard deviation (SD), when the data are normally distributed; odd ratio (OR) was used with 99% confidence interval to determine association, *p* value <0.05 was considered statistically significant.

**Results**: Female represent 81% of the total patients, while male represent only 19%, with ratio male : female equal to 1: 4.3, most of the patients were adults over 20 years old, with mean age ± SD was 35.8 ± 13.7 years. The most common signs were joint pain (95.1%), fever (92.3%), persistent fatigue (83.8%), followed by joint swelling (69.7%), Photosensitivity (54.4%), Renal involvement (52.8%), Weigh loss (49.3%) and alopecia (49.3%), while other SLE signs were less frequent. Consideration of clinical signs of systemic lupus erythematosus associated with high titer of Epstein-Barr virus IgG antibody. There was a significant association between elevated Epstein-Barr virus IgG antibody titers with fever (OR = 15.2), and joint pain (OR = 8.4), weight loss (OR = 3.9), and joint swelling (OR = 3.6), while there was no statistically significant correlation with other sing markers.

**Conclusion**: EBV may have an important role in SLE pathogenesis and activity, SLE male:female ratio equals 1:4.3, most patients were adults over 20 years of age, and the most common signs of SLE were joint pain, fever and persistent fatigue. Follow-up of patients with EBV infection is very important to assess the status of patients at risk of developing SLE. Further studies are needed to achieve a more comprehensive understanding of EBV as a trigger for SLE and other autoimmune diseases, severity of signs, risk factors, and characteristics of SLE patients.

**Keywords**: Epstein-Barr virus, elevated titer antibody, systemic lupus erythematosus (SLE), IgG EBV antibody, viral capsid antigen (VCA)

**INTRODUCTION**

Systemic lupus erythematosus is an autoimmune disease with no apparent pathogenesis. This illness is described by polyclonal B-cell initiation and distorted T-cell function with the occurrence of multiple auto-antibodies and damaged cellular immunity. It is supposed that both environmental and genetic factors be part of the cause to development of the disease1,2. Infection with bacteria and viruses are important environmental factors that can initiate and participate in the pathogenesis of SLE. The Epstein-Barr virus (EBV) is one of the most important causes. This is because Epstein-Barr is homologous to some proteins that produce an autoimmune humoral response3,4. These molecular mimics may play a vital role in the antibody induction by EBV infection in SLE patients. More recently, Harley *et al*. 5 accounted that approximately 50% of the SLE risk sites are occupied by the EBNA-2 protein and numerous co-clusteres with factors of transcription, presenting a fundamental new perception on the pathogenesis mechanism of SLE. In 1971 the first positive association connecting EBV infection with SLE was found6. From the time when numerous researchers have used different angles to explore the option of this association. Though, preceding studies failed to reveal a consistent association. The earliest and single systematic review updated regarding the association between SLE and seropositivity for distinct EBV antibodies was that of Hanlon *et al*.7. The authors discovered a statistically significant higher seroprevalence of viral capsid antigen (VCA) IgG but not EBNA1 in the cases contrasted to the controls. Meta-analysis of early antigen (EA)/D IgG and VCA IgA also showed significantly higher ORs in the cases group compared to the control group. Many studies have since been published and may help in more fully estimating the association. In addition, some authors postulated that the increase in antibodies in SLE was brought about by generalized immune hyper-reactivity in lupus rather than by any specific property of the EBV. It was later thought that the best way to clarify this question would be at the DNA level8-11. SLE can affect persons of both sexes, all ages, and all ethnic groups. However, more than 90% of new patients presenting with SLE are women in their childbearing years12,13. SLE is a disease that affects multiple systems and its symptoms vary widely. Several studies have from the time when published and may assist to completely estimate the association. In addition, several authors hypothesized that the increase in auto-antibodies in SLE is due to generalized immune hyper-reactivity in SLE more readily than to any specific characteristic of EBV. It was later they thought that the best way to make clear this question would be at the DNA level8-11. SLE can involve people of both genders, all ethnic groups, and all ages. In spite of this, more than 90% of new patients with SLE are women in their reproductive ages 12,13. Lupus is a multisystem disease with a variety of symptoms. Compound organ impairment in SLE is due to the creation of auto-antibodies, which include auto-antibodies to antigens in the vascular tissues, brain tissues, renal tissues and, ribosomes, nuclear antigens, and phospholipids. Inflammation and intracranial vascular lesions which include vasculitis and thrombosis have been associated with local secretion of cytokines12, 13 . Additionally, recent data indicated that both renal and neuropsychological intervention negatively affect the five-year survival rate. However, the neuropsychological involvement did not alter for the ten-year survival rate, regardless of the fact that the association of the nervous system in SLE persists poorly understood14. Fatigue in SLE is likely to be multifactorial and is not only associated with disease activity, but also with complications such as hypothyroidism or anemia12.

In recent years, viral infection and autoimmune diseases have been well studied in Yemen, where many studies have been conducted in this aspect13-31, but only one previous study discussed SLE in Yemen12, and another study discussed the association of EBV with diseases Autoimmune (rheumatoid arthritis)13. However, there is no study associated with EBV infection with clinical features and SLE in Yemen and this study is the first to discuss this topic. Therefore, the aims of this study was to determine the patient characteristics and clinical manifestations of systemic lupus erythematosus and to know the association of positive IgG with high titer of EBV-VCA with systemic lupus erythematosus - in addition to knowing the association of positive IgG with high titer of EBV-VC with the occurrence of different clinical features of SLE patients.

**MATERIALS AND METHODS**

This study was conducted over a period of one year from October 2020 to November 2021. A total of 142 Yemeni patients were enrolled, who were admitted to the medical wards and/or to the medical clinics of Al-Thawra Hospital in Sana'a City. All patients met four or more of the American College of Rheumatology (ACR) criteria for a diagnosis of SLE32. Specially designed questionnaires were analyzed with retrospective of relevant data such as patients' age, gender, clinical manifestations at presentation and during follow-up, and their exposure to possible risk factors for lupus erythematosus. Treatments, both at the start and during follow-up appointments, were also recorded, in addition to any complications.

Laboratory data include anemia (hemoglobin <11 g/dL), leukopenia (white blood cells <4000/mm9), and thrombocytopenia (platelets <100000/mm9). In vitro data also comprised elevated erythrocyte sedimentation rate, positive ANA, positive rheumatoid factor, and high anti-DNA and anti-SM antibody. ANA was considered by two diverse methods: enzyme-linked immunosorbent assay (ELISA), and indirect immunofluorescence (IIF), anti-ds deoxyribonucleic acid (anti-dsDNA) and anti-Smith antibodies (anti-Sm) were measured by ELISA (INOVA Diagnostic Toolkit, San Diego, California, USA).

Lupus nephritis was established by kidney biopsy, which was classified consistent with WHO classification II, III, IV or V33. Photosensitivity has been identified by certain skin lesions caused by sunlight. The various drugs used in treating patients ranged from non-steroidal anti-inflammatory drugs (NSAIDs), hydroxychloroquine and steroids, to intermittent cyclophosphamide with intravenous methylprednisolone in lupus nephritis. Warfarin was an anticoagulant used in cases of venous thrombosis.

**EBV detection**: Whole blood samples were taken and serum separated for determination of EBV IgG antibodies using the ELISA method. Epstein-Barr virus IgG ELISA (VCA) was used for the qualitative determination of IgG-class antibodies against Epstein-Barr virus antigen (VCA) in human serum or plasma. The test was performed according to the manufacturer's instructions (Demeditec Diagnostics GmbH, Germany).

**Data analysis:** The *odds ratio* (*OR*) for the association of high positive IgG titer of EBV-VC with clinical presentations of SLE, and their Cornfield 95% confidence limits, were calculated by the analysis of a single table (the simplest contingency table being the 2 x 2 table). Furthermore, the Chi-square (*X2*) value for statistical significance was calculated using Yates’ continuity correction. However Fisher's exact test was employed for small cell sizes with a two-tailed probability value (*P*), using the Epi-Info Version 6 software (Centers for Disease Control and Prevention, Atlanta, Georgia, USA).

**Ethical consideration:** Ethical approval for this study, No: 754 dated September 27, 2020 was obtained Ethical approval was acquired from the ethics committee of the Faculty of Medicine and Health Sciences, Sana'a University prior to data collection. An official letter was obtained from the Faculty of Medicine and Health Sciences, Sana'a University, to be submitted to the administration of Al-Thawra Hospital to facilitate the conduct of this research work. A consent form was completed by each participant.

**RESULTS**

Female represent 81% of the total patients, while male represent only 19%, with ratio male : female equal to 1: 4.3. Considering age, most of the patients were adults over 20 years old, with mean age ± SD was 35.8 ± 13.7 years (Table 1). The most common signs were joint pain (95.1%), fever (92.3%), persistent fatigue (83.8%), followed by joint swelling (69.7%), Photosensitivity (54.4%), renal involvement ( 52.8%), weigh loss (49.3%), and alopecia (49.3%) less frequent such as ankle swelling (33.8%), and chest pain during deep breathing (28.9). %), and cutaneous lupus (discoid lupus) (26.8%), while butterfly rash (malaria rash) , oral ulcers and serositis were very rare (15.5%, 10.6% and 9.2% respectively) (Table 2). In the current study, the positive rate of Epstein-Barr Virus IgG among our SLE patients was 97.2%, and 56.3% of them had high level of the antibody ≥ 51 IU (Table 3). There was a significant negative association between the higher positive rate of Epstein-Barr Virus IgG and male patients with the rate being only 33.3% compared to 61.7% for females (Table 4). There was an association between a higher positive rate of Epstein-Barr virus IgG and an age group of 20-29 years where 77.1% of this group had a high level of EBV antibody, with an *OR* of 3.7, 95% *CI*. = 1.4-8.3, *p* = 0.004 (Table 4). Consideration of clinical signs of systemic lupus erythematosus associated with high titer of Epstein-Barr virus IgG antibody. There was a significant association between elevated Epstein-Barr virus IgG antibody titers with fever (*OR* = 15.2, *CI* = 1.8-122, *X2* = 10.8, *p* = 0.001), and joint pain (*OR* = 8.4, *CI* = 1.0-72, *X2* = 5.2, *p* = 0.02), weight loss (*OR* = 3.9, *CI* = 1.96-8, *X2* = 15.3, *p* < 0.0001), and joint swelling (*OR* = 3.6, *CI* = 1.7 - 7.5, *X2* = 11.5, *p* < 0.0001 ), while there was no statistically significant correlation between the high titer of IgG antibody to Epstein-Barr virus with other sing markers (Table 5).

**DISCUSSION**

Systemic lupus erythematosus is an autoimmune disease characterized by the production of autoantibodies and the involvement of multiple organ systems, and is more common in females than males35,36. This is one of the first studies in Yemen that aimed to determine the prevalence of diagnostic antibodies, clinical signs, and association with EB virus infection in SLE patients. In the current study, the ratio of male to female patients was 1: 4.3. This result is in agreement with the result of the previous study in Yemen by Al-Shamahi *et al.* where the ratio of males to females was 1:312. Also, the predominant prevalence of SLE among females compared to males in the current study is similar to other studies in different geographical regions where they reported a more dominant prevalence of SLE among females than males with a ratio higher than 1:4.3 (1:7.2; 1:9.8 and 1: 9.9)37-39. This difference can likely be attributed to the undiagnosed SLE status in many parts of Yemen where facilities to perform the baseline ELISA assay are often not available. Moreover, the lower incidence of SLE among Yemeni females compared to females of other countries could be explained by the under-diagnosis among females in Yemen due to socio-economic factors that prevent many females from accessing health care centers or hospitals. Another explanation is that males and females in Yemen are relatively at risk or predisposing factors for the development of SLE with approximately the same frequency but at different points. These factors may include genetic, hormonal, and environmental factors40,41. In conclusion, SLE, like many autoimmune diseases, affects females more than males, with a richness ratio of about 9 to 142,43. The X chromosome carries immune-related genes, which can mutate and contribute to the onset of SLE. The Y chromosome does not contain specific mutations associated with autoimmune diseases44. Also, hormonal mechanisms could explain the increased incidence of SLE in females. The onset of SLE can be attributed to elevated hydroxylation of estrogen and abnormally low levels of androgens in females. In addition, differences in GnRH signaling have also been shown to contribute to the onset of SLE. While females are more likely to relapse than males, the severity of these relapses is the same for both sexes. In addition to hormonal mechanisms, specific genetic influences located on the X chromosome may also contribute to the development of SLE. Studies show that the X chromosome can determine levels of sex hormones. A study showed an association between Klinefelter syndrome and SLE. XXY males with SLE have an abnormal X-Y translocation resulting in partial triplication of the PAR1 gene region45-47.

In the current study, the mean age of SLE patients was 35.8 ± 13.7 years which is slightly older than the age previously reported in Yemen by Al-Shamahy *et al.*12 where the mean age of SLE patients was 28.8 years. Moreover, this study had a mean age (35.8 years) of our patients slightly older than that reported from Spain by Font *et al*,48 in which the mean ​​​​​​​age of the SLE patients is 29 years. In the current study in Yemen, the majority of patients (90.1%) were adults over 19 years of age and (9.9%) were under 19 years of age. This is similar to the previous study in Yemen where the majority of patients (88.6%) were adults and (11.4%) children under 15 years of age12. This is also similar to what was reported in Saudi Arabia by Albullah 46; mostly patients over 15 years old. The higher rate among adults may be related to the sex hormones, which play an important role in triggering the disease47.

Systemic lupus erythematosus is one of several diseases known as a "great imitator" because it is often imitated or mistaken for other diseases. SLE is a classic component of the differential diagnosis40 because SLE symptoms vary widely and come and go unexpectedly. Thus the diagnosis can be elusive, with some people having unexplained symptoms of SLE for years. In the current study, the frequencies of the major clinical and serological features of our patients, compared to the other populations, are represented in Table 4. The results of this study showed that the most common clinical symptom in Yemeni patients with SLE was joint pain, which was present in (95.1%). In contrast to other studies in western Saudi Arabia, it occurred in (9.2%) only49, and in Iran (30.2%)50. This can be explained in our patients that joint pain is an important symptom due to the health education background. Moreover, this symptom has been associated not only with disease activity or complications such as anemia but also with pain, depression, poor sleep quality, poor fitness and marked lack of social support12. Fever also was common in our patients (92.3%), and the temperature usually showed diurnal variation being high in afternoon and evening. It is slightly higher than that reported in Yemen previously in which fever also was common with 81.9% 12 , also it was more higher than that reported in Spain (42.0%) and Saudi Arabia (30.0%)38,48. The results of this study showed one of the most frequent clinical symptom in Yemeni patients with SLE was fatigue which was present in (83.8%), this is similar to that reported in Yemen by Al-Shamahy *et al* 12 in which the rate of fatigue among SLE was 84.6%. In contrast to other studies in western Saudi Arabia, it occurred in (9.5%) only49, and in Iran (32.2%) only 50. In the current study, cutaneous lupus (discoid lupus) is present in 26.8% and butterfly rash (malar lupus) in 15.5% of our patients. These results are lower than those reported in literature where up to 70% of people with lupus experience some skin symptoms. The three main categories of lesions are chronic (discoid) lupus, subacute cutaneous lupus, and acute cutaneous lupus. People with discoid lupus may develop thick, red, scaly patches on the skin. Similarly, subacute cutaneous lupus appears as red, scaly patches of skin but with distinct edges. Acute cutaneous lupus appears as a rash. Some have the classic rash (known as butterfly rash) associated with the disease51 as this rash occurs in 30 to 60% of people with SLE52. Also, the butterfly rash (malar rash) that occurred in 15.5% of our patients is lower than what was previously reported in Yemen where malar rash was present in 52.3% of SLE patients12 and lower than the results in Lebanon (52.0% ) and Spain (54.0%)53,54.

In the current study, the positive rate of Epstein-Barr Virus IgG among our SLE patients was 97.2%, and 56.3% of them had high level of the antibody ≥ 51 IU which indicate active infections2. To clear this result, there is need to understand that, systemic lupus erythematosus is an autoimmune disease without clear pathogenesis. This disease is characterized by polyclonal B cell activation and altered T cell function with the presence of multiple auto-antibodies and impaired cell-mediated immunity. It is believed that both genetic and environmental factors contribute to disease development2. Bacteria and virus infections are major important environmental factors that may be initiated and involved in the pathogenesis of SLE. The Epstein–Barr virus (EBV) is of particular interest. It has been reported that Epstein–Barr nuclear antigen-1 (EBNA-1) has a high degree of homology with some proteins that cause an autoimmune humoral response3,4. This molecular mimicry may play an essential role in the induction of antibodies by EBV infection in SLE patients. Recently, Harley *et al.* reported that nearly half of SLE risk loci are occupied by the EBNA-2 protein and many co-cluster with transcription factors, providing an essential new perspective on the mechanism of SLE pathogenesis5.

The association in the current study between , the positive rate of Epstein-Barr Virus IgG and SLE is similar to that reported by Evans *et al* in which the first positive association between EBV infection and SLE was found in 19716. Since then, many researchers have used various angles to investigate the possibility of this link. However, previous studies have failed to detect a consistent association. The first and only systematic review that updated on the association between SLE and sero-positivity for different EBV antibodies was that of Hanlon *et al*.7. These authors found a statistically significant higher sero-prevalence of viral capsid antigen (VCA) IgG but not EBNA1 in cases compared with controls. Meta-analyses for early antigen (EA)/D IgG and VCA IgA also significantly demonstrated higher ORs in cases compared with controls7. In addition, the association in the current study between , the positive rate of Epstein-Barr Virus IgG and SLE can be explained by the some authors postulated that the increase in antibodies in SLE was brought about by generalized immune hyper-reactivity in lupus rather than by any specific property of the EBV8,54. So the best way to clarify this question would be at the DNA level estimation of EBV genome load.

Considering the gender in the current study, there was a significant negative association between the higher positive rate of Epstein-Barr Virus IgG and male patients with the rate being only 33.3% compared to 61.7% for females (Table 4). The present results are similar to those reported by Ulff-Møller *et al*.55, Shoenfeld *et al*.56, Chen *et al.*57 as the high level rate EBV among females with lupus erythematosus comparing to lower rate in SLE male patients. Considering the age in the current study, there was an association between a higher positive rate of Epstein-Barr virus IgG and an age group of 20-29 years where 77.1% of this group had a high level of EBV antibody, with an *OR* of 3.7, 95% *CI.* = 1.4-8.3, *p* = 0.004 (Table 4). While there was a low rate of high-level EBV antibodies in children and young adults (age less than 20 years). This result is similar to James *et al.*3, and Tsai *et al.*11 as slightly higher OR values ​​were observed in the second decade SLE patients comparing with younger adults and pediatric patients. This may be due to the fact that in this age SLE patients tend to be more infected with EBV, which is consistent with James *et al*.3.

A high level of Epstein-Barr virus IgG antibodies was significantly associated with the incidence of clinical signs such as joint pain as the associated *odds ratio* was 8.4 with 95% *CI* = 1-72, *p* = 0.02; also with fever where the associated *odds ratio* was 15.2 with 95% *CI* = 1.8 -122, *p* = 0.001; in addition to joint swelling where the associated *odds ratio* was 3.6 with 95% *CI* = 1.7 - 7.5, *p* = 0.00006 (Table 5). These symptoms are usually associated with active EBV infection, so our results may indicate that most of our patients have active EBV infection and these findings were confirmed by Cohen58 and Cohen *et al*. 59 as these symptoms only accompany active cases among patients with SLE.

**CONCLUSION**

EBV may have an important role in SLE pathogenesis and activity, SLE male : female ratio equals 1:4.3, most patients were adults over 20 years of age, and the most common signs of SLE were joint pain, fever and persistent fatigue. Follow-up of patients with EBV infection is very important to assess the status of patients at risk of developing SLE. Further studies are needed to achieve a more comprehensive understanding of EBV as a trigger for SLE and other autoimmune diseases, severity of signs, risk factors, and characteristics of SLE patients.

**ACKNOWLEDGMENT**

The authors also would like to acknowledge the Ministry of Health and population, Sana’a, Yemen for support.

**CONFLICT OF INTEREST**

There is no conflict of interest associated with this study.

**AUTHOR'S CONTRIBUTION**

The first author, Mohammed Ismail Al-Mansor who performed the study filed, and the rest of the authors were analyzed the data, wrote, reviewed and edited the paper.

**REFERENCES**

1.Li ZX, Zeng S, Wu HX, Zhou1 Y. The risk of systemic lupus erythematosus associated with Epstein–Barr virus infection: a systematic review and meta‑analysis. Clinical and Experimental Medicine 2019; 19:23–36. https://doi.org/10.1007/s10238-018-0535-0

2. Munz C, Lunemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol. 2009;9(4):246–58. https://doi.org/ [10.1038/nri2527](https://doi.org/10.1038/nri2527)

3. James JA, Scofield RH, Harley JB. Lupus humoral autoimmunity after short peptide immunization. Ann N Y Acad Sci. 1997;815:124–7. https://doi.org/ [10.1111/j.1749-6632.1997.tb52054.x](https://doi.org/10.1111/j.1749-6632.1997.tb52054.x)

4. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 2005;11(1):85–9. https://doi.org/ 10.1038/nm1167

5. Harley JB, Chen X, Pujato M, *et al*. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 2018;50(5):699–707. https://doi.org/ 10.1038/s41588-018-0102-3

6. Evans AS, Rothfield NF, Niederman JC. Raised antibody titres to EB virus in systemic lupus erythematosus. Lancet. 1971;1(7691):167–8. https://doi.org/ 10.1016/s0140-6736(71)91937-4.

7. Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. 2014;16(1):R3. https://doi.org/  [10.1186/ar4429](https://doi.org/10.1186%2Far4429)

8. Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol. 1998;16(3):289–94.

9. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;100(12):3019–26. https://doi.org/  [10.1172/JCI119856](https://doi.org/10.1172%2FJCI119856)

10. Lau CS, Yuen KY, Chan KH, Wong RW. Lack of evidence of active lytic replication of Epstein-Barr and cytomegaloviruses in patients with systemic lupus erythematosus. Chin Med J (Engl). 1998;111(7):660–5.

11. Tsai YT, Chiang BL, Kao YF, Hsieh KH. Detection of Epstein- Barr virus and cytomegalovirus genome in white blood cellsfrom patients with juvenile rheumatoid arthritis and childhood systemic lupus erythematosus. Int Arch Allergy Immunol. 1995;106(3):235–40. https://doi.org/ 10.1159/000236848.

12. Al-Shamahy, Dhaifallah NHM, Al-Ezzy YM. Clinical and Laboratory Manifestations of Yemeni Patients with Systemic Lupus Erythematosus. Sultan Qaboos University Med J 2014; 14 (1): e80-87. https://doi.org/ [10.12816/0003340](https://doi.org/10.12816/0003340)

13. Othman, A. M., E. A. Alyosfi, and H. A. AL-Shamahy. “The association of Epstein-Barr virus antibodies with rheumatoid arthritis among Yemeni patients in Sana’a city”. *Universal Journal of Pharmaceutical Research*, vol. 2, no. 4, July 2017, https://doi.org/ 10.22270/ujpr.v2i4.R4.

14. Ogaili, M. A. O., E. A. Al-gunaid, H. A. Al-Shamahy, and B. M. Jaadan. “Survey of safety practices in diarrheal treatment centers: cholera treatment centers in Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 5, no. 4, Sept. 2020, https://doi.org/ 10.22270/ujpr.v5i4.432.

15. Saad Al-Dabis, E. M., H. A. Al-Shamahy, M. M. S. Al-Hadad, and E. H. Al-Shamahi. “Prevalence of hepatitis G virus among patients with chronic liver disease and healthy individuals, Sana’a city-Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 3, no. 6, Jan. 2019, https://doi.org/ 10.22270/ujpr.v3i6.216.

16. Nassar, M. Y., H. A. Al-Shamahy, and A. M. M. AL-Barq. “Evaluation of the immune response to polio vaccine in malnourished children in Sana’a city”. *Universal Journal of Pharmaceutical Research*, vol. 3, no. 2, May 2018, pp. 29-33, https://doi.org/ 10.22270/ujpr.v3i2.137.

17. Amran, O. A. A., H. A. Al-Shamahy, A. M. Al Hadad, and B. M. Jaadan. “Explosion of hepatitis b and c viruses among hemodialysis patients as a result of hemodialysis crisis in Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 4, no. 5, Nov. 2019, https://doi.org/ 10.22270/ujpr.v4i5.311.

18. Hanash, S. H., H. A. Al-Shamahy, and M. H. S. Bamshmous. “prevalence and genotyping of hepatitis c virus in hemodialysis patients and evaluation of HCV-core antigen test in screening patients for dialysis in Sana’a city, Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 4, no. 2, May 2019, https://doi.org/ 10.22270/ujpr.v4i2.251.

19. Al-Kebsi, A. M., A. M. Othman, A.-K. M. A. Abbas, E. M. Madar, H. A. Al-Shamahy, K. M. Al-Gaffari, S. M. N. Daname, and F. L. Motareb. “Sero-prevalence of hepatitis C virus among dental clinic workers in Sana’a city- Yemen and the risk factors contributing for its infection”. *Universal Journal of Pharmaceutical Research*, vol. 2, no. 5, Sept. 2017, https://doi.org/ 10.22270/ujpr.v2i5.R6.

20. Mutahar, D. J. A., K. S. A. Al-Khamesy, K. A.-K. A. Al-Moyed, H. A. Al-Shamahy, and M. M. Al-Shehari. “Pattern of liver disease admissions at a tertiary government hospital in Sana’a, Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 7, no. 4, Sept. 2022, https://doi.org/ 10.22270/ujpr.v7i4.807.

21. Al-Shamahy, H. A., M. A. Ajrah, A. G. Al-Madhaji, B. B. M. Al-Fraji, M. A. A. Ajrah, M. M. A. Al- Hajj, and A. M. Al-Hadad. “Prevalence and potential risk factors of hepatitis B virus in a sample of children in two selected areas in Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 4, no. 3, July 2019, https://doi.org/ 10.22270/ujpr.v4i3.269.

22. AL-Marrani, W. H. M., and H. A. Al-Shamahy. “Prevalence of HBV and HCV; and their associated risk factors among public health center cleaners at selected public health centers in Sana’a city-Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 3, no. 5, Nov. 2018, https://doi.org/ 10.22270/ujpr.v3i5.204.

23. Al-Shami, H. Z., Z. A. M. Al-Mutawakal, A. I. M. Al-Kholani, M. A. Al-Haimi, A. M. Al-Haddad, R. A. Ahmed, A. A. Al-Somainy, and H. A. Al-Shamahy. “Prevalence of hepatitis a virus, hepatitis B virus, and hepatitis C virus, among patients with hepatic jaundice in Sana’a city, Yemen: a hospital based study”. *Universal Journal of Pharmaceutical Research*, vol. 6, no. 6, Jan. 2022, https://doi.org/ 10.22270/ujpr.v6i6.693.

24. Al-kadassy, A. M., A. F. S. Al-Ashiry, and H. A. Al-Shamahy. “Sero-epidemiological study of hepatitis B, C, HIV and treponema pallidum among blood donors in hodeida city- yemen”. *Universal Journal of Pharmaceutical Research*, vol. 4, no. 2, May 2019, https://doi.org/ 10.22270/ujpr.v4i2.256.

25. Al-Ademi, D. A. A., A. H. Al-Harazi, H. A. Al-Shamahy, and B. M. Jaadan. “Detection of influenza viruses among hospitalized cases suffering from severe acute respiratory illness (sari) in Sana’a city, Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 4, no. 4, Sept. 2019, https://doi.org/ 10.22270/ujpr.v4i4.296.

26. Abdullah Almoaish, M. A., H. A. Al-Shamahy, M. M. Ali Al- Hajj, S. M. Nasser Dainamah, and A. G. Al-Madhaji. “Prevalence of cytomegalovirus igg antibodies, potential risk factors and awareness of congenital cytomegalovirus among female doctors”. *Universal Journal of Pharmaceutical Research*, vol. 3, no. 5, Nov. 2018, https://doi.org/ 10.22270/ujpr.v3i5.199.

27. Al-Shawkany, E. M., A.-A.-R. M. AlShawkany, S. S. Bahaj, A. M. Othman, H. A. Al-Shamahy, and A. A. M. Al-Ankoshy. “Prevalence of different hepatitisB virus genotypes and risk factors associated among selected Yemeni patients with chronic hepatitis b infection”. *Universal Journal of Pharmaceutical Research*, vol. 6, no. 3, July 2021, doi:10.22270/ujpr.v6i3.603.

28. Al-Shamahy, H. A., and A. A. Ishak. “Trends and causes of morbidity in part of children in the city of Sana’a, Yemen 1978-2018: findings of single children’s health center”. *Universal Journal of Pharmaceutical Research*, vol. 5, no. 6, Jan. 2021, https://doi.org/ 10.22270/ujpr.v5i6.504.

29. Al-Shamahi, E. Y., N. M. Muhsin, E. H. Al-Shamahi, and H. A. Al-Shamahy. “Patterns of uveitis at a tertiary referral center in Yemen: one central retrospective study”. *Universal Journal of Pharmaceutical Research*, vol. 7, no. 2, May 2022, https://doi.org/ 10.22270/ujpr.v7i2.743.

30. Mufadhal, E. A., F. K. Al-Showafi, H. A. Al-Shamahy, and E. M. Al-zabidi. “The association between levels of hepcidin, iron status and micro-inflammation markers among haemodialysis”. *Universal Journal of Pharmaceutical Research*, vol. 4, no. 5, Nov. 2019, https://doi.org/ 10.22270/ujpr.v4i5.313.

31. El-Aghbary, D. A., A. G. Al-Jaaidi, K. A. Al-Moyed, A. B. A. Al-Robasi, and A. M. Othman. “Seroprevalence of anti-mannose binding lectin autoantibodies in patients with rheumatoid arthritis in Sana’a city- Yemen”. *Universal Journal of Pharmaceutical Research*, vol. 3, no. 2, May 2018, pp. 34-37, https://doi.org/ 10.22270/ujpr.v3i2.138.

32. Verma J, Arora V, Marwaha V, Kumar A, Das N. Association of leukocyte CR1 gene transcription with the disease severity and renal involvement in systemic lupus erythematosus. Lupus 2005; 14:273–9.

33. Alkhotani A. Neuropsychiatric Lupus. Sultan Qaboos Univ Med J 2013; 13:19–25.

34. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369:587–96.

35.Wang GS, Zhang M, Li XP, et al. Ultraviolet B exposure of peripheral blood mononuclear cells of patients with systemic lupus erythematosus inhibits DNA methylation. Lupus 2009; 18: 1037-1044.

36. Lisnevskaia L, Murphy G, Isenberg D. "Systemic lupus erythematosus". Lancet 2014; **384** (9957): 1878–1888. https://doi.org/ [10.1016/s0140-6736(14)60128-8](https://doi.org/10.1016%2Fs0140-6736%2814%2960128-8).

37. Rabbani MA, Siddiqui BK, Tahir MH, *et al.* Do Clinical Manifestations of Systemic Lupus Erythematosus in Pakistan. Correlate with rest of Asia? J. Pak. Med. Assoc.2006; 56(5): 222-227.

38. Al-Arfaj AS, Khalil N. Clinical and immunological manifestation in 624 SLE patients in Suadi Arabia. Lupus 2009; 18: 456-473.

39. Cervera R, Khamashta MA, Hughes GRV. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009; 18: 869-874.

40. Rahman A, Isenberg DA. "Systemic lupus erythematosus". The New England Journal of Medicine 2008; **358** (9): 929-39.  https://doi.org/[10.1056/NEJMra071297](https://doi.org/10.1056%2FNEJMra071297)

41. Davis LS, Reimold AM. ["Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850311). Rheumatology 2017; **56** (suppl\_1): i100–i113. https://doi.org/ [10.1093/rheumatology/kew417](https://doi.org/10.1093%2Frheumatology%2Fkew417).

42. Murphy G, Isenberg D. ["Effect of gender on clinical presentation in systemic lupus erythematosus"](https://doi.org/10.1093%2Frheumatology%2Fket160). Rheumatology 2013; **52** (12): 2108–2115. https://doi.org/ [10.1093/rheumatology/ket160](https://doi.org/10.1093%2Frheumatology%2Fket160).

43. Danchenko N, Satia JA, Anthony MS. "Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden". Lupus 2006; **15** (5): 308–318. https://doi.org/[10.1191/0961203306lu2305xx](https://doi.org/10.1191%2F0961203306lu2305xx).

44. Tsokos GC. "Systemic lupus erythematosus". The New England Journal of Medicine 2011; **365** (22): 2110–2121. https://doi.org/ [10.1056/NEJMra1100359](https://doi.org/10.1056%2FNEJMra1100359).

45. Zandman-Goddard G, Peeva E, Shoenfeld Y. "Gender and autoimmunity". Autoimmunity Reviews 2007; **6** (6): 366–372.  https://doi.org/ [10.1016/j.autrev.2006.10.001](https://doi.org/10.1016%2Fj.autrev.2006.10.001).

46. Alballa SR. Systemic lupus erythematosus in Saudi patients. Clin. Rheum.1995; 14: 342-346.

47. Hellmann DB, Stone JH. Musculoskeletal Disorders. In: Tierney LM, McPhee SJ, Papadakis MA. Current Medical Diagnosis and Treatment. 45thedition. New York, Chicago, San Francesco. Lange Medical Books/McGraw-Hill 2006; 807-864.

48. Font J, Cervera R, Ramos-Casals M, *et al*. Clusters of clinical and immunologic features in systemic lupus erythematosus: Analysis of 600 patients from a single center. Semi. Arthritis. Rheum 2004; 33 (4): 217-230. https://doi.org/  10.1053/s0049-0172(03)00133-1.

49. Qari FA. Clinical pattern of systemic lupus erythematosus in Western Saudi Arabia. Saudi Med. J. 2002; 23 (10): 1247-1250.

50. Nazarinia MA, Ghaffarpasand F, Shamsdin A, *et al*. Systemic lupus erythematosus in the Fars Province of Iran. Lupus 2008; 17: 221-227. https://doi.org/  [10.1177/0961203307086509](https://doi.org/10.1177/0961203307086509)

51.Tebbe B, Orfanos CE. "Epidemiology and socioeconomic impact of skin disease in lupus erythematosus". Lupus 1997; **6** (2): 96–104 https://doi.org/ [10.1177/096120339700600204](https://doi.org/10.1177%2F096120339700600204).

52. Harris JP, Weisman MH, eds.  [Head and neck manifestations of systemic disease](https://books.google.com/books?id=31yUl-V90XoC&pg=PA6). New York 2007; Informa Healthcare. p. 6. [ISBN](https://en.wikipedia.org/wiki/ISBN_(identifier)) [9781420017564](https://en.wikipedia.org/wiki/Special:BookSources/9781420017564).

53. Uthman F, Nasr F, Kassak K, Masri A-F. Systemic lupus erythematosus in Lebanon. Lupus 1999; 8: 713-715. <https://doi.org/10.1191/096120399678841016>

54. Wells GA, Shea B, O’Connell D, *et al.* The Newcastle –Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohric a/progr ams/clini cal\_epide miolo gy/oxfor dasp 2011.

55. Ulff-Møller CJ, Nielsen NM, Rostgaard K, *et al*. Epstein–Barr virus-associated infectious mononucleosis and risk of systemic lupus erythematosus. Rheumatology 2010; **49**, 1706-12. https://doi.org/

56. Shoenfeld Y, Berkun Y, Zandman-Goddard G, *et al.* . Infectious antibodies in systemic lupus erythematosus 38.patients. Lupus 2009; **18**, 1129-35. https://doi.org/ 10.1177/0961203309345729.

57. Chen C-J, Lin K-H, Lin S-C*, et al* . High prevalence of immunoglobulin a antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J Rheumatol 2005; **32**, 44-7.

58.Cohen JI. "Epstein-Barr Infections, Including Infectious Mononucleosis". In Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds.). Harrison's principles of internal medicine  2008; (17th ed.). New York: McGraw-Hill Medical Publishing Division. pp. 380–91. [ISBN](https://en.wikipedia.org/wiki/ISBN_(identifier)) [978-0-07-146633-2](https://en.wikipedia.org/wiki/Special:BookSources/978-0-07-146633-2).

59. Cohen, Jonathan; Powderly, William G.; Opal, Steven M. [Infectious Diseases](https://books.google.com/books?id=Dhq3DAAAQBAJ&pg=PA79) 2016, Elsevier Health Sciences p. 79. [ISBN](https://en.wikipedia.org/wiki/ISBN_(identifier)) [9780702063381](https://en.wikipedia.org/wiki/Special:BookSources/9780702063381). [Archived](https://web.archive.org/web/20170911003200/https:/books.google.com/books?id=Dhq3DAAAQBAJ&pg=PA79) from the original on 2017-09-11.

Table 1: Age and Gender Distribution of Systemic Lupus Erythematosus Patients Tested for Epstein-Barr Virus, in Sana'a City

|  |  |  |
| --- | --- | --- |
| **Characters** | **Number** | **percentage** |
| **Gender (Ratio male : female = 1:4.3)** | | |
| Female | 115 | 81 |
| Male | 27 | 19 |
| **Age groups** | | |
| ≥ 19 years | 14 | 9.9 |
| 20 – 29 years | 35 | 24.6 |
| 30-39 years | 42 | 29.6 |
| 40 – 49 years | 25 | 17.6 |
| ≥ 50 years | 26 | 18.3 |
| **Total** | **142** | **100** |
| Mean age | 35.8 years |  |
| SD | 13.7 years |  |
| Median | 35 years |  |
| Mode | 30 years |  |
| Min | 12 years |  |
| Max | 80 years |  |
|  |  |  |

Table 2: The clinical signs of the Systemic Lupus Erythematosus Patients Tested for Epstein-Barr Virus, in Sana'a City (n=142)

|  |  |  |
| --- | --- | --- |
| **Signs** | **Number** | **Percentage** |
| Joints pain | 135 | 95.1 |
| Fever | 131 | 92.3 |
| Constant fatigue | 119 | 83.8 |
| Joint swelling | 99 | 69.7 |
| Photosensitivity | 77 | 54.4 |
| Renal involvement | 75 | 52.8 |
| Weigh loss | 70 | 49.3 |
| Alopecia | 70 | 49.3 |
| Hypertension | 52 | 36.6 |
| Swollen ankle | 48 | 33.8 |
| Pain in chest during deep breath | 41 | 28.9 |
| Cutaneous lupus ([discoid lupus](https://en.wikipedia.org/wiki/Discoid_lupus_erythematosus)) | 38 | 26.8 |
| Butterfly rash ([malar rash](https://en.wikipedia.org/wiki/Malar_rash)) | 22 | 15.5 |
| Oral ulcers | 15 | 10.6 |
| Serositis | 13 | 9.2 |

Table 3: The Epstein-Barr Virus IgG antibody titration among Systemic Lupus Erythematosus Patients, in Sana'a City

|  |  |  |
| --- | --- | --- |
| **IgG antibody titration** | **Number** | **Percentage** |
| ≥ 10 IU | 4 | 2.8 |
| 11-40 IU | 21 | 14.8 |
| 41 – 50 IU | 37 | 26.1 |
| ≥ 51 IU | 80 | 56.3 |
| **Total positive** | **138** | 97.2% |
| Mean | 47.1 U |  |
| SD | 9.6 IU |  |
| Median | 51 IU |  |
| Mode | 53 IU |  |
| Min | 3.2 IU |  |
| Max | 57 IU |  |

Table 4: Age and Gender of Systemic Lupus Erythematosus Patients associated with high titer of IgG antibody of Epstein-Barr Virus (n=80)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characters** | **No (%)**  **N=80** | **OR** | **95% CI** | **X2** | **P value** |
| **Gender** | | | | | |
| Female n=115 | 71 (61.7) | 1.2 | 0.4-3.2 | 0.09 | 0.76 |
| Male n=27 | 9 (33.3) | 0.3 | 0.12-0.71 | 7.1 | 0.007 |
| **Age groups** | | | | | |
| ≥ 19 years n=14 | 9 (64.3) | 1.4 | 0.45-4.5 | 0.39 | 0.52 |
| 20 – 29 years n=35 | 27 (77.1) | 3.7 | 1.4-8.3 | 8.2 | 0.004 |
| 30-39 years n=42 | 23 (54.8) | 0.59 | 0.28-1.2 | 1.9 | 0.16 |
| 40 – 49 years n=25 | 10 (40) | 0.44 | 0.18-1.08 | 3.3 | 0.06 |
| ≥ 50 years n=26 | 11 (42.3) | 0.49 | 0.2-1.2 | 2.5 | 0.11 |
| Total n=142 | 80(56.3) |  |  |  |  |

Table 5: Clinical signs of Systemic Lupus Erythematosus associated with high titer of IgG antibody of Epstein-Barr Virus

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Signs** | **No (%)** | **OR** | **95% CI** | **X2** | **P value** |
| Fever n=131 | 79 (60.3) | 15.2 | 1.8-122 | 10.8 | 0.001 |
| Joints pain n=135 | 79 (58.5) | 8.4 | 1 -72 | 5.2 | 0.02 |
| Weigh loss n=70 | 51 (72.9) | 3.9 | 1.96-8 | 15.3 | <0.0001 |
| Joint swelling n=99 | 65 (65.7) | 3.6 | 1.7-7.5 | 11.5 | <0.0001 |
| Cutaneous lupus ([discoid lupus](https://en.wikipedia.org/wiki/Discoid_lupus_erythematosus)) n=38 | 26 (68.4) | 2 | 0.9-4.3 | 3.1 | 0.07 |
| Butterfly rash ([malar rash](https://en.wikipedia.org/wiki/Malar_rash)) n=22 | 15 (68.2) | 1.8 | 0.7-4.7 | 1.4 | 0.22 |
| Oral ulcers n=15 | 10 (66.7) | 1.6 | 0.5-5.3 | 0.72 | 0.39 |
| Skin rash n=38 | 23 (60.5) | 1.3 | 0.6-2.7 | 0.37 | 0.54 |
| Serositis n=13 | 8 (61.5) | 1.3 | 0.3-4 | 0.15 | 0.69 |
| Alopecia n=70 | 39 (55.7) | 0.95 | 0.49-1.8 | 0.02 | 0.88 |
| Swollen ankle n=48 | 25 (52) | 0.77 | 0.38-1.6 | 0.53 | 0.46 |
| Hypertension n=52 | 21(40.4) | 0.35 | 0.17-0.71 | 8.4 | 0.003 |
| Pain in chest during deep breath n=41 | 25 (61) | 0.3 | 0.1-0.6 | 9.1 | 0.002 |
| Photosensitivity n=77 | 33 (42.6) | 0.28 | 0.14-0.58 | 12.4 | <0.0001 |
| Constant fatigue n=119 | 68 (57.1) | 0.2 | 0.07-1.07 | 3.8 | 0.05 |
| Renal involvement n=75 | 23 (30.7) | 0.07 | 0.03-0.17 | 42 | <0.0001 |